Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 23Terminated 6Unknown 5Withdrawn 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Non-Hodgkin 11Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Pancreatic Neoplasms 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Brain Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Bendamustine Hydrochloride × Clear all
NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Columbia University

Phase 1/2 Terminated
23 enrolled 13 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Washington University School of Medicine

Phase 1 Terminated
15 enrolled
Plasma cell

Multiple Myeloma

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Hoosier Cancer Research Network

Phase 1/2 Terminated
32 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

NYU Langone Health

Phase 2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01484626 2018-07-10

BVRD

Loyola University

Phase 1/2 Terminated
3 enrolled 4 charts
Plasma cell

Multiple Myeloma

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NYU Langone Health

Phase 2 Terminated
24 enrolled 3 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡